Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX20
|
| gptkbp:brand |
gptkb:Tivdak
|
| gptkbp:chemicalClass |
monoclonal antibody conjugate
|
| gptkbp:developer |
gptkb:Seagen
gptkb:Genmab |
| https://www.w3.org/2000/01/rdf-schema#label |
tisotumab vedotin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent MMAE
targets tissue factor |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
bleeding fatigue peripheral neuropathy eye toxicity |
| gptkbp:target |
tissue factor (TF)
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Tivdak
|
| gptkbp:bfsLayer |
6
|